IART
INTEGRA LIFESCIENCES HOLDINGS CORP
NASDAQ · Healthcare · Medical - Devices · US
$13.45
+1.82%Year over year
Reported trailing growth
- Revenue
- +1.6%
- EBITDA
- +175.1%
- EBIT
- +231.0%
- EPS
- +98.6%
- Free cash flow
- +181.8%
- Operating cash flow
- +20.4%
Forward estimates
Based on analyst estimates
- Revenue
- +2.6%
- EBITDA
- +101.1%
- EPS
- +2854.7%
Three-year CAGR
- Revenue
- +1.6%
- EBITDA
- —
- EBIT
- -34.1%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026